Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendations
Koh, Christopher , Zhao, Xiongce, Sakiani, Sasan, Talwalkar, Jayant A., Samala, Niharika , Liang, T. Jake

Hepatology | June 14, 2013 | Volume: 58 | Issue: 6 | Pages: 2142-2152

10.1002/hep.26578 | PMID 23775835 Get It

Concise review: Mesenchymal stem cell treatment for ischemic kidney disease
Zhu, Xiang-Yang, Lerman, Lilach O. , Lerman, Amir

Stem Cells | June 14, 2013 | Volume: 31 | Issue: 9 | Pages: 1731-1736

10.1002/stem.1449 | PMID 23766020 Get It

Abstract Ischemic kidney diseases are common clinical entities that bear high mortality and morbidity and may lead to irreversible loss of kidney function. Their pathophysiology is multifaceted, involves complex hormonal-immunological-cellular interactions, and leads to damage in multiple cell types, which is often resistant to conventional therapy. Thus, novel strategies are needed to repair the renal parenchyma and preserve kidney function. Mesenchymal stem cells (MSC) confer renal protection through paracrine/endocrine effects and to some degree possibly by direct engraftment. Their anti-inflammatory and immune-modulatory properties target multiple cascades in the mechanisms of ischemic kidney disease. This review focuses on recent progress on the use of MSC to prevent kidney injury in ischemic kidney injury, with a focus on the chronic form.
Managing iatrogenic pneumothorax and chest tubes
Loiselle, Andrea, Parish, James M., Wilkens, James A., Jaroszewski, Dawn E.

Journal of Hospital Medicine | June 14, 2013 | Volume: 8 | Issue: 7 | Pages: 402-408

10.1002/jhm.2053 | PMID 23765922 Get It

Iatrogenic pneumothorax has become an increasingly recognized complication of routine outpatient procedures, such as transthoracic needle biopsies of the lung and transbronchial lung biopsies. Patients with clinically significant pneumothorax are typically managed with evacuation via a percutaneously placed catheter or chest tube. Tube thoracotomy and chest tube management have traditionally been performed by cardiothoracic surgeons; however, with the increasing number of interventional radiologists and interventional pulmonologists, more chest tubes are being placed by specialists who do not admit and manage patients in the hospital setting. The responsibility for the admission of these patients to the hospital service has fallen to the internist. Hospitalists caring for such patients are often expected to manage the chest tube. General internal medicine training and the existing medical literature provide few guidelines to assist with this issue. We present a discussion of the current published literature and our management algorithms for hospitalists caring for patients admitted with iatrogenic pneumothorax. Journal of Hospital Medicine 2013;8:402–408. © 2013 Society of Hospital Medicine
Faculty Opinions recommendation of SDH mutations establish a hypermethylator phenotype in paraganglioma.
Maher, Jim

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 14, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718013617.793477437 Get It

Long-Term Bioavailability After a Single Oral or Intramuscular Administration of 600,000 IU of Ergocalciferol or Cholecalciferol: Implications for Treatment and Prophylaxis
Cipriani, Cristiana , Romagnoli, Elisabetta , Pepe, Jessica , Carlucci, Luciano , Piemonte, Sara, Nieddu, Luciano , Minisola, Salvatore , Russo, Stefania , McMahon, Donald J. , Singh, Ravinder J. , Cipriani, Cristiana

The Journal of Clinical Endocrinology & Metabolism | June 14, 2013 | Volume: 98 | Issue: 7 | Pages: 2709-2715

10.1210/jc.2013-1586 | PMID 23766519 Get It

The SPARC Score: A Multifactorial Outcome Prediction Model for Patients Undergoing Radical Cystectomy for Bladder Cancer
Eisenberg, Manuel S., Boorjian, Stephen A. , Cheville, John C. , Thompson, R. Houston, Thapa, Prabin , Kaushik, Dharam , Frank, Igor

Journal of Urology | June 14, 2013 | Volume: 190 | Issue: 6 | Pages: 2005-2010

10.1016/j.juro.2013.06.022 | PMID 23770147 Get It

Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Liu, Mohan , Wickerham, D. Lawrence, Schaid, Daniel J. , Wang, Liewei , Kubo, Michiaki , Costantino, Joseph P., Vogel, Victor G. , Paik, Soonmyung , Ames, Matthew M. , Jenkins, Gregory D. , Batzler, Anthony , Flockhart, David A., Nakamura, Yusuke , Weinshilboum, Richard M. , Ingle, James N. , Mushiroda, Taisei , Goetz, Matthew P. , Carlson, Erin E. , Wolmark, Norman , Weinshilboum, Richard M.

Cancer Discovery | June 14, 2013 | Volume: 3 | Issue: 7 | Pages: 812-825

10.1158/2159-8290.cd-13-0038 | PMID 23764426 Get It

Abstract The selective estrogen receptor modulators (SERM) tamoxifen and raloxifene can reduce the occurrence of breast cancer in high-risk women by 50%, but this U.S. Food and Drug Administration-approved prevention therapy is not often used. We attempted to identify genetic factors that contribute to variation in SERM breast cancer prevention, using DNA from the NSABP P-1 and P-2 breast cancer prevention trials. An initial discovery genome-wide association study identified common single-nucleotide polymorphisms (SNP) in or near the ZNF423 and CTSO genes that were associated with breast cancer risk during SERM therapy. We then showed that both ZNF423 and CTSO participated in the estrogen-dependent induction of BRCA1 expression, in both cases with SNP-dependent variation in induction. ZNF423 appeared to be an estrogen-inducible BRCA1 transcription factor. The OR for differences in breast cancer risk during SERM therapy for subjects homozygous for both protective or both risk alleles for ZNF423 and CTSO was 5.71. Significance: This study identified novel, functionally polymorphic genes involved in the estrogen-dependent regulation of BRCA1 expression, as well as a novel mechanism for genetic variation in SERM therapeutic effect. These observations, and definition of their underlying mechanisms, represent steps toward pharmacogenomically individualized SERM breast cancer prevention. Cancer Discov; 3(7); 812–25. ©2013 AACR. See related commentary by Machiela and Chanock, p. 728 This article is highlighted in the In This Issue feature, p. 705
A Radiation-Induced Meningioma “Cures” A Complex Dural Arteriovenous Fistula
Link, Michael J. , Copeland, William

Journal of Neurological Surgery Part A: Central European Neurosurgery | June 13, 2013 | Volume: 74 | Issue: S 01 | Pages: e215-e220

10.1055/s-0033-1345099 | PMID 23765916 Get It

Exercise right heart catheterization for inferior vena cava obstruction: Confirming the hemodynamic significance of an anatomic lesion
Eleid, Mackram F. , Bjarnason, Haraldur , Frye, Robert L. , Nishimura, Rick A. , Bjarnason, Haraldur

Catheterization and Cardiovascular Interventions | June 13, 2013 | Volume: 83 | Issue: 1 | Pages: No page available

10.1002/ccd.25062 | PMID 23766235 Get It

Retroperitoneal fibrosis is a rare condition characterized by the presence of inflammatory and fibrous retroperitoneal tissue that surrounds and often encases abdominal structures. In this report we describe an unusual presentation of retroperitoneal fibrosis and inferior vena cava (IVC) obstruction that was unidentified by noninvasive testing and ultimately diagnosed using exercise right heart catheterization and venography. Exercise hemodynamic catheterization revealed a high pressure gradient across the IVC obstruction during exercise that resulted in reduced preload and inappropriately low cardiac output reserve. The patient ultimately underwent angioplasty and stenting of the obstruction resulting in resolution of his symptoms. © 2013 Wiley Periodicals, Inc.
Quantification of Incomplete Revascularization and its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial Validation of the Residual SYNTAX Score
Farooq, Vasim , Bourantas, Christos V. , Zhang, Yao‐Jun , Muramatsu, Takashi , Feldman, Ted , Holmes, David R. , Mack, Michael J. , Morice, Marie Claude, Ståhle, Elisabeth , Colombo, Antonio , Vries, Ton de, Morel, Marie-angèle , Dawkins, Keith D., Mohr, Friedrich W., Serruys, Patrick W. , Morice, Marie‐Claude, Kappetein, A. Pieter

Circulation | June 13, 2013 | Volume: 128 | Issue: 2 | Pages: 141-151

10.1161/circulationaha.113.001803 | PMID 23766350 Get It

Background— The residual Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Score is an objective measure of the degree and complexity of residual stenosis after percutaneous coronary intervention (PCI). Methods and Results— In the randomized PCI cohort of the SYNTAX Trial (n=903), the baseline and residual SYNTAX Scores were calculated. Subjects with a residual SYNTAX Score of 0 were defined as having undergone complete revascularization (CR), and a residual SYNTAX Score >0 as incomplete revascularization (ICR). Five-year clinical outcomes were stratified by CR and ICR (tertiles of the residual SYNTAX Score: >0–4, >4–8, and >8). In the PCI cohort, the mean baseline and residual SYNTAX Scores were 28.4±11.5 and 4.5±6.9, respectively. The mean Δ SYNTAX Score (representative of the burden of disease removed by PCI) was 23.8±10.9. The residual SYNTAX Score was distributed as follows: CR, 0 (n=386, 42.7%); ICR, >0 to 4 (n=184, 20.4%), >4 to 8 (n=167, 18.5%), >8 (n=153, 16.9%). A progressively higher residual SYNTAX Score was shown to be a surrogate marker of increasing clinical comorbidity and anatomic complexity. Subjects with CR or residual SYNTAX Scores ≤8 had comparable 5-year mortality (CR, 8.5%; residual SYNTAX Score >0–4, 8.7%; >4–8, 11.4%; P =0.60). A residual SYNTAX Score >8 was associated with 35.3% all-cause mortality at 5-years ( P <0.001). Stratified analyses in the predefined medical treated diabetic and left main subgroups yielded similar results. Conclusions— The residual SYNTAX Score was shown to be a powerful indicator of 5-year mortality in the SYNTAX Trial. The residual SYNTAX Score may aid in determining a reasonable level of revascularization. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00114972.